Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo
Article
Fu, C. H. Y., Antoniades, M., Erus, G., Garcia, J. A., Fan, Y., Arnone, D., Arnott, S. R., Chen, T., Choi, K. S., Chin Fatt, C., Frey, N. B., Frokjaer, V. G., Ganz, M., Godlewska, B. R., Hassel, S., Ho, K., McIntosh, A. M., Qin, K., Rotzinger, S., Sacchet, M. D., Savitz, J., Shou, H., Singh, A., Stolicyn, A., Strigo, I., Strother, S. C., Tosun, D., Victor, T. A., Wei, D., Wise, T., Zahn, R., Anderson, I. M., Craighead, W. E., Deakin, J. F. W., Dunlop, B. W., Elliott, R., Gon, Q., Gotlib, I. H., Harmer, C. J., Kennedy, S. H., Knudsen, G. M., Mayberg, H. S., Paulus, M. P., Qiu, J., Trivedi, M. H., Whalley, H. C., Yan, G-C., Young, A. H. and Davatzikos, C. 2023. Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo. Nature Mental Health. 2, pp. 164-176. https://doi.org/10.1038/s44220-023-00187-w
Authors | Fu, C. H. Y., Antoniades, M., Erus, G., Garcia, J. A., Fan, Y., Arnone, D., Arnott, S. R., Chen, T., Choi, K. S., Chin Fatt, C., Frey, N. B., Frokjaer, V. G., Ganz, M., Godlewska, B. R., Hassel, S., Ho, K., McIntosh, A. M., Qin, K., Rotzinger, S., Sacchet, M. D., Savitz, J., Shou, H., Singh, A., Stolicyn, A., Strigo, I., Strother, S. C., Tosun, D., Victor, T. A., Wei, D., Wise, T., Zahn, R., Anderson, I. M., Craighead, W. E., Deakin, J. F. W., Dunlop, B. W., Elliott, R., Gon, Q., Gotlib, I. H., Harmer, C. J., Kennedy, S. H., Knudsen, G. M., Mayberg, H. S., Paulus, M. P., Qiu, J., Trivedi, M. H., Whalley, H. C., Yan, G-C., Young, A. H. and Davatzikos, C. |
---|---|
Abstract | Major depressive disorder (MDD) is a heterogeneous clinical syndrome with widespread subtle neuroanatomical correlates. Our objective was to identify the neuroanatomical dimensions that characterize MDD and predict treatment response to selective serotonin reuptake inhibitor (SSRI) antidepressants or placebo. In the COORDINATE-MDD consortium, raw MRI data were shared from international samples (N=1,384) of medication-free individuals with first episode and recurrent MDD (N=685) in a current depressive episode of at least moderate severity, but not treatment resistant depression, as well as healthy controls (N=699). Prospective longitudinal data on treatment response were available for a subset of MDD individuals (N=359). Treatments were either SSRI antidepressant medication (escitalopram, citalopram, sertraline) or placebo. Multi-center MRI data were harmonized, and HYDRA, a semi-supervised machine learning clustering algorithm, was utilized to identify patterns in regional brain volumes that are associated with disease. MDD was optimally characterized by two neuroanatomical dimensions which exhibited distinct treatment responses to placebo and SSRI antidepressant medications. Dimension 1 was characterized by preserved gray and white matter (N=290 MDD), whereas Dimension 2 was characterized by widespread subtle reductions in gray and white matter (N=395 MDD) relative to healthy controls. Although there were no significant differences in age of onset, years of illness, number of episodes, or duration of current episode between dimensions, there was a significant interaction effect between dimensions and treatment response. Dimension 1 showed a significant improvement in depressive symptoms following treatment with SSRI medication (51.1%), but limited changes following placebo (28.6%); in contrast, Dimension 2 showed comparable improvements to either SSRI (46.9%) or placebo (42.2%) (β=-18.3, 95% CI (-34.3 to -2.3), p=0.03). Findings from this case-control study indicate that neuroimaging-based markers can help identify the disease-based dimensions that comprise MDD and predict treatment response. |
Journal | Nature Mental Health |
Journal citation | 2, pp. 164-176 |
ISSN | 2731-6076 |
Year | 2023 |
Publisher | Nature Research |
Publisher's version | License File Access Level Anyone |
Supplemental file | File Access Level Anyone |
Supplemental file | File Access Level Anyone |
Digital Object Identifier (DOI) | https://doi.org/10.1038/s44220-023-00187-w |
Publication dates | |
Online | 12 Jan 2024 |
Feb 2024 | |
Publication process dates | |
Accepted | 17 Nov 2023 |
Deposited | 28 Nov 2023 |
Funder | National Institute of Mental Health |
Copyright holder | © 2023, The Authors |
https://repository.uel.ac.uk/item/8wz62
Download files
Publisher's version
s44220-023-00187-w (1).pdf | ||
License: CC BY 4.0 | ||
File access level: Anyone |
Supplemental file
44220_2023_187_MOESM1_ESM.pdf | ||
File access level: Anyone |
Reporting Summary.pdf | ||
File access level: Anyone |
178
total views50
total downloads2
views this month2
downloads this month